https://www.businesswire.com/news/home/202503...al-Officer
“Matt’s deep experience in launching multiple neuroscience and psychiatric therapeutics will be invaluable as we prepare for our first potential FDA approval of MM120 ODT,” said Rob Barrow, Chief Executive Officer of MindMed.